The analysis showed cabozantinib was associated with an improvement in progression-free survival (PFS) compared with placebo in patients with advanced GI neuroendocrine tumors (NET), which was a ...

Analyst David Lebowitz from Citi maintained a Buy rating on Exelixis (EXEL – Research Report) and keeping the price target at $38.00. David Lebowitz has given his Buy rating due to a combination ...